PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 76 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2014. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $4,746,000 | -60.1% | 1,249,005 | -46.6% | 0.00% | 0.0% |
| Q4 2019 | $11,908,000 | +104.4% | 2,339,670 | +103.0% | 0.00% | 0.0% |
| Q3 2019 | $5,827,000 | -15.2% | 1,152,792 | +3.5% | 0.00% | -50.0% |
| Q2 2019 | $6,875,000 | +48.6% | 1,114,302 | +11.8% | 0.00% | +100.0% |
| Q1 2019 | $4,626,000 | -41.6% | 997,020 | -47.2% | 0.00% | 0.0% |
| Q4 2018 | $7,922,000 | +49.8% | 1,886,542 | +123.6% | 0.00% | 0.0% |
| Q3 2018 | $5,290,000 | -9.9% | 843,843 | +15.6% | 0.00% | -50.0% |
| Q2 2018 | $5,871,000 | +26.9% | 730,229 | +17.7% | 0.00% | 0.0% |
| Q1 2018 | $4,626,000 | +28.2% | 620,240 | +2.3% | 0.00% | +100.0% |
| Q4 2017 | $3,608,000 | -18.7% | 606,510 | +0.6% | 0.00% | -50.0% |
| Q3 2017 | $4,438,000 | -1.0% | 603,094 | -8.6% | 0.00% | 0.0% |
| Q2 2017 | $4,482,000 | -25.6% | 660,183 | +3.4% | 0.00% | 0.0% |
| Q1 2017 | $6,028,000 | +18.1% | 638,633 | +8.1% | 0.00% | 0.0% |
| Q4 2016 | $5,103,000 | +73.6% | 590,726 | +27.2% | 0.00% | +100.0% |
| Q3 2016 | $2,940,000 | +52.4% | 464,479 | +1.6% | 0.00% | 0.0% |
| Q2 2016 | $1,929,000 | -1.3% | 457,275 | +1.9% | 0.00% | 0.0% |
| Q1 2016 | $1,955,000 | -38.4% | 448,564 | -13.4% | 0.00% | -50.0% |
| Q4 2015 | $3,173,000 | +6.8% | 517,764 | -0.4% | 0.00% | 0.0% |
| Q3 2015 | $2,972,000 | -8.8% | 519,711 | +18.9% | 0.00% | 0.0% |
| Q2 2015 | $3,260,000 | +27.1% | 437,084 | +1.9% | 0.00% | +100.0% |
| Q1 2015 | $2,565,000 | -20.7% | 428,990 | +0.3% | 0.00% | -50.0% |
| Q4 2014 | $3,233,000 | +48.8% | 427,790 | +2.1% | 0.00% | +100.0% |
| Q3 2014 | $2,173,000 | +21.7% | 418,801 | +1.1% | 0.00% | 0.0% |
| Q2 2014 | $1,785,000 | +5.7% | 414,329 | +0.3% | 0.00% | 0.0% |
| Q1 2014 | $1,688,000 | +6.6% | 412,943 | +39.0% | 0.00% | 0.0% |
| Q4 2013 | $1,583,000 | +19.8% | 297,007 | +13.1% | 0.00% | 0.0% |
| Q3 2013 | $1,321,000 | +44.1% | 262,645 | +27.7% | 0.00% | 0.0% |
| Q2 2013 | $917,000 | – | 205,662 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
| Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
| Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
| Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
| BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
| PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
| FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
| Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |